CasLoc logo
All Cases PTAB Litigations UPC Oppositions

AbbVie Inc. v. Mylan Pharmaceuticals Inc.

1:13-cv-01072

Overview

Case Number 1:13-cv-01072
Filing Date 2013-06-14
Status Terminated
Termination Date 2015-10-07
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Laboratories Ltd. Operating Company

Represented By

2 Attorneys Listed

Richard L. Horwitz

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Bindu Ann George Palapura

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000
Fax: +1 (302) 778-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Mylan Pharmaceuticals Inc. Operating Company

Represented By

13 Attorneys Listed

Richard L. Horwitz

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Timothy H. Kratz

Email: tkratz@kratzandbarry.com

Robert L. Florence

Email: robertflorence@parkerpoe.com

Michael F. Nullet

UNDELIVERABLE EMAIL 6/21/2016

Meghan M. Rachford

Email: mrachford@mcguirewoods.com

Marcus A. Barber

Email: mbarber@kasowitz.com

Jessica M. Hauth

Email: jhauth@mcguirewoods.com

George J. Barry , III

Email: gbarry@kratzandbarry.com

David Ellis Moore

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Cedric C. Y. Tan

UNDELIVERABLE EMAIL 5/2/2022

Brie L.B. Buchanan

Email: bbuchanan@mcguirewoods.com

Bindu Ann George Palapura

Potter Anderson & Corroon, LLP

Tel: +1 (302) 984-6000
Fax: +1 (302) 778-6000

1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951

Anil H. Patel

Email: anil.patel@klgates.com

Plaintiff

Abbvie Deutschland GMBH & Co. KG Operating Company

Represented By

1 Attorneys Listed

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

AbbVie Inc. Operating Company

Represented By

8 Attorneys Listed

Robert C. Stanley

Email: robert.stanley@finnegan.com

Mindy L. Ehrenfried

Email: mindy.ehrenfried@finnegan.com

Jonathan R. Davies

Email: jdavies@cooley.com

Derek James Fahnestock

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Corinne Miller LaGosh

UNDELIVERABLE EMAIL 10/7/15

Barbara R. Rudolph

Email: barbara.rudolph@finnegan.com

Amanda K. Murphy

Email: amanda.murphy@finnegan.com

Mary B. Graham

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Third Party Defendant

Alkermes, Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

🇺🇸
U.S. District Courts 9 proceedings
🏛️
USPTO PTAB Trials Counterparts in force
🇪🇺
Unified Patent Court (UPC) Counterparts in force
🇩🇪
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): 🇺🇸 US
Parallel Proceedings Across Jurisdictions (9 found):
U.S. Courts: 9
U.S. District Court 2017-01-13
1:17-cv-00047

AbbVie Inc. v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2016-05-27
1:16-cv-00398

AbbVie Inc. v. Amneal Pharmaceuticals, LLC

Asserted Patent
Status: DED
U.S. District Court 2015-10-02
1:15-cv-00889

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2014-09-25
1:14-cv-01236

AbbVie Inc. v. Mylan Pharmaceuticals Inc.

U.S. Family Sibling (["US8691878"])
Status: DED
U.S. District Court 2014-09-05
1:14-cv-01137

AbbVie Inc. v. Hetero Labs Limited

U.S. Family Sibling (["US8691878"])
Status: DED
U.S. District Court 2014-07-18
1:14-cv-00959

AbbVie Inc. v. Aurobindo Pharma Limited

Asserted Patent
Status: DED
U.S. District Court 2013-07-03
2:13-cv-00645

AbbVie Inc. v. Roxane Laboratories Inc.

Asserted Patent
Status: OHSD
U.S. District Court 2013-05-15
1:13-cv-00852

AbbVie Inc. v. Hetero USA Inc.

Asserted Patent
Status: DED
U.S. District Court 2012-04-10
1:12-cv-00457

AbbVie Inc. v. Roxane Laboratories Inc.

Asserted Patent
Status: DED
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

9 Patents

There are 9 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US6232333
Pharmaceutical composition
Filed: 1997-11-07
Issued: 2001-05-15
Expired (Term Ended)
Expires: 2017-11-07
US7141593
Pharmaceutical formulations
Filed: 2000-05-22
Issued: 2006-11-28
Expired (Term Ended)
Expires: 2020-05-22
US7432294
Pharmaceutical formulations
Filed: 2006-10-12
Issued: 2008-10-07
Expired (Term Ended)
Expires: 2026-10-12
US7148359
Polymorph of a pharmaceutical
Filed: 2005-05-04
Issued: 2006-12-12
Expired (Term Ended)
Expires: 2025-05-04
US7364752
Solid dispersion pharamaceutical formulations
Filed: 2000-11-10
Issued: 2008-04-29
Expired (Term Ended) +688d PTA
Expires: 2022-09-29

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. § 283) Statutorily Barred

Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term — No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

48

Dispositive

6

Granted

1

Denied

0

Pending / Review

39

Motions by Category

Claim Construction / Markman Filing 35 Procedural / Extension Motion 7 Motion to Dismiss 6

Key Dispositive Motions & Rulings

Motion to Dismiss Pending / Under Review
SO ORDERED Granting 128 STIPULATION of Dismissal of Certain Counterclaims, and withdrawal of Motion to Dismiss (D.I. 98 ), filed by Mylan Laboratories Ltd., Myl...
Entry #130 • 2015-01-22 Document →
Motion to Dismiss Pending / Under Review
STIPULATION TO EXTEND TIME AbbVie's Time to Reply to Mylan's Answering Brief in Opposition to Motion to Dismiss Mylan's Counterclaims to January 22, 2015 - file...
Entry #119 • 2015-01-09 Document →
Motion to Dismiss Pending
SO ORDERED, re 119 STIPULATION TO EXTEND TIME to Reply to Answering Brief in Opposition to Motion to Dismiss Mylan's Counterclaims to January 22, 2015, filed by...
Entry #— • 2015-01-09
Motion to Dismiss Pending / Under Review
[SEALED] ANSWERING BRIEF in Opposition re 98 MOTION to Dismiss Second, Third, Fifth, and Sixth Counterclaims filed by Mylan Laboratories Ltd., Mylan Pharmaceuti...
Entry #117 • 2015-01-05 Document →
Motion to Dismiss Pending / Under Review
MOTION to Dismiss Second, Third, Fifth, and Sixth Counterclaims - filed by AbbVie Inc., Abbvie Deutschland GMBH & Co. KG. (Fahnestock, Derek) Modified on 12/16/...
Entry #98 • 2014-12-15 Document →
Motion to Dismiss Pending / Under Review
[SEALED] OPENING BRIEF in Support re 98 MOTION to Dismiss Second, Third, Fifth, and Sixth Counterclaims, filed by AbbVie Inc., Abbvie Deutschland GMBH & Co. KG....
Entry #99 • 2014-12-15 Document →

Docket Entries

(278 total)
Pleading / Complaint

COMPLAINT filed against Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-1310284.) - filed by AbbVie Inc.. (Attachments: # 1 Exhibit A-C, # 2 Civil Cover Sheet)(cla, ) (Entered: 06/17/2013)

Entry #1 • 2013-06-14
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (cla, ) (Entered: 06/17/2013)

Entry #2 • 2013-06-14
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 5/1/13. Date of Expiration of Patent: SEE FORM.Thirty Month Stay Deadline: 11/1/2015. (cla, ) (Entered: 06/17/2013)

Entry #3 • 2013-06-14
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,232,333 B1; 7,141,593 B1; 7,432,294 B2;. (cla, ) (Entered: 06/17/2013)

Entry #4 • 2013-06-14
1

Disclosure Statement pursuant to Rule 7.1 filed by AbbVie Inc.. (cla, ) (Entered: 06/17/2013)

Entry #5 • 2013-06-14
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc